NVP-BEZ235 (hydro<wbr/>chloride)

NVP-BEZ235 (hydrochloride)

CAT N°: 21185
Price:

From 48.00 40.80

NVP-BEZ235 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies.{18570,18573} It inhibits PI3K isoforms and mutants with low nanomolar IC50 values, leading to growth arrest in the G1 phase.{18570,18572} Through its effects on PI3K, NVP-BEZ235 inhibits VEGF-induced angiogenesis.{18571} By directly blocking cell growth and indirectly inhibiting angiogenesis, it has potential in both solid tumors and in metastatic melanoma therapy.{18574,18575}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-?,?-dimethyl-benzeneacetonitrile, monohydrochloride
  • Correlated keywords
    • 915019-65-7 1146702-52-4 BEZ-235 235NX anti-cancer rapamycin G-1
  • Product Overview:
    NVP-BEZ235 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies.{18570,18573} It inhibits PI3K isoforms and mutants with low nanomolar IC50 values, leading to growth arrest in the G1 phase.{18570,18572} Through its effects on PI3K, NVP-BEZ235 inhibits VEGF-induced angiogenesis.{18571} By directly blocking cell growth and indirectly inhibiting angiogenesis, it has potential in both solid tumors and in metastatic melanoma therapy.{18574,18575}

We also advise you